NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis $21.06 +1.75 (+9.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$19.16▼$21.0850-Day Range$17.40▼$24.9452-Week Range$12.07▼$25.91Volume498,401 shsAverage Volume269,542 shsMarket Capitalization$581.47 millionP/E RatioN/ADividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Castle Biosciences alerts: Email Address Castle Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.2% Upside$31.00 Price TargetShort InterestBearish6.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 10 Articles This WeekInsider TradingSelling Shares$688,627 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.66) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.63 out of 5 starsMedical Sector672nd out of 936 stocksMedical Laboratories Industry15th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.56% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Castle Biosciences has recently increased by 54.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 2.6 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Castle Biosciences this week, compared to 3 articles on an average week.Search Interest9 people have searched for CSTL on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $688,627.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to decrease in the coming year, from ($1.66) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -18.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -18.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Castle Biosciences Stock (NASDAQ:CSTL)Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More CSTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Stock News HeadlinesJuly 25 at 1:35 PM | finance.yahoo.comInvestors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three yearsJuly 22, 2024 | businesswire.comCastle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of MelanomaJuly 26, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…July 22, 2024 | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Expected to Post Q2 2024 Earnings of ($0.16) Per ShareJuly 21, 2024 | americanbankingnews.comCastle Biosciences (NASDAQ:CSTL) Trading 5.4% Higher July 11, 2024 | businesswire.comCastle Biosciences Honored with Top Workplaces AwardsJune 24, 2024 | businesswire.comRecent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® TestJune 20, 2024 | businesswire.comCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…June 14, 2024 | businesswire.comCastle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award WinnerMay 30, 2024 | businesswire.comCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceMay 29, 2024 | businesswire.comNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisMay 15, 2024 | businesswire.comCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceMay 14, 2024 | finance.yahoo.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 14, 2024 | businesswire.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 10, 2024 | finance.yahoo.comCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"May 10, 2024 | businesswire.comCastle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”May 8, 2024 | finance.yahoo.comLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultSee More Headlines Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees540Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$37.00 Low Stock Price Target$25.00 Potential Upside/Downside+49.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,470,000.00 Net Margins-12.28% Pretax Margin-12.23% Return on Equity-7.91% Return on Assets-6.95% Debt Debt-to-Equity Ratio0.02 Current Ratio9.25 Quick Ratio9.02 Sales & Book Value Annual Sales$219.79 million Price / Sales2.60 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.43Miscellaneous Outstanding Shares27,610,000Free Float25,619,000Market Cap$572.08 million OptionableOptionable Beta0.93 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Derek J. Maetzold (Age 62)Founder, CEO, President & Director Comp: $1.45MMr. Frank Stokes (Age 53)CFO & Treasurer Comp: $849.36kMs. Kristen M. Oelschlager R.N. (Age 56)Chief Operating Officer Comp: $782.7kMr. Tobin W. Juvenal (Age 64)Chief Commercial Officer Comp: $782.7kCamilla ZuckeroVice President of Investor Relations & Corporate AffairsMs. Alice Bahner IzzoSenior Vice President of MarketingMr. Kevin DomanVice President of SalesMs. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesDr. Robert W. Cook Ph.D. (Age 52)Senior Vice President of Research & Development Dr. Matthew Goldberg M.D.Senior Vice President of MedicalMore ExecutivesKey CompetitorsBiodesixNASDAQ:BDSXGenetronNASDAQ:GTHExagenNASDAQ:XGNRenalytixNASDAQ:RNLXNational HealthCareNYSE:NHCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,583 shares on 7/26/2024Ownership: 0.350%Legato Capital Management LLCBought 14,155 shares on 7/26/2024Ownership: 0.051%Summit Global InvestmentsBought 23,812 shares on 7/22/2024Ownership: 0.086%SG Americas Securities LLCBought 26,989 shares on 7/12/2024Ownership: 0.098%Harbor Capital Advisors Inc.Bought 99,001 shares on 7/9/2024Ownership: 0.502%View All Insider TransactionsView All Institutional Transactions CSTL Stock Analysis - Frequently Asked Questions How have CSTL shares performed this year? Castle Biosciences' stock was trading at $21.58 at the beginning of the year. Since then, CSTL stock has decreased by 2.4% and is now trading at $21.06. View the best growth stocks for 2024 here. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.28. The company had revenue of $72.97 million for the quarter, compared to analysts' expectations of $68.34 million. Castle Biosciences had a negative trailing twelve-month return on equity of 7.91% and a negative net margin of 12.28%. When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Top institutional shareholders of Castle Biosciences include Harbor Capital Advisors Inc. (0.50%), Bank of New York Mellon Corp (0.35%), SG Americas Securities LLC (0.10%) and Summit Global Investments (0.09%). Insiders that own company stock include Derek J Maetzold, Daniel Bradbury, Ellen Goldberg, Tiffany Olson, Kristen M Oelschlager and Bernhard E Spiess. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM) and Teladoc Health (TDOC). This page (NASDAQ:CSTL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
